1. Introduction {#s0005}
===============

Coronaviruses (CoVs) are positive-sense RNA enveloped viruses which derive their name from the crown-like spikes on their surface and they belong to Coronaviridae family. They are classified into four main subgroups- alpha, beta, gamma, and delta depending on their genomic structure \[[@bb0005]\]. Alpha- and beta coronaviruses cause respiratory infections in humans and gastroenteritis in other mammals \[[@bb0010],[@bb0015]\]. Until the last year, only six different coronaviruses causing infection in humans were known. Four of this (HCoV-NL63, HCoV-229E, HCoV-OC43 and HKU1) cause mild common cold-type symptoms in healthy individuals and the other two which caused epidemics in the last two decades. The severe acute respiratory syndrome coronavirus (SARS-CoV) caused a SARS epidemic in 2002--2003 with a 10% mortality rate. Likewise, the Middle East respiratory syndrome coronavirus (MERS-CoV) caused a disastrous pandemic in 2012 leading to 37% mortality \[[@bb0005]\]. All coronaviruses infecting humans usually known to have intermediate hosts such as bats or rodents \[[@bb0020]\]. Previous outbreaks of SARS-CoV and MERS-CoV involved civet cats and dromedary camels for their direct transmission to humans \[[@bb0005]\]. A new coronavirus caused an outbreak of the pulmonary disease in Wuhan (the capital of Hubei province in China) in December 2019 and has since spread across different parts of the world \[[@bb0025],[@bb0030]\]. Since its RNA genome shows about 82% identity to that of the SARS coronavirus (SARS-CoV), the new virus has been termed as SARS-CoV-2 \[[@bb0035]\]. However, both these viruses belong to the same clade of the genus *Betacoronavirus* \[[@bb0025],[@bb0030]\]. The SARS-CoV-2 caused a disease known as COVID-19. At the initial outbreak, cases were linked to the Huanan seafood and animal market in Wuhan but active human-to-human transmission caused exponential growth in the number of reported cases. The World Health Organization (WHO) confirmed the outbreak a pandemic on March 11, 2020. There have been \>170,000 cumulative cases worldwide accounting for approximately 3.7% case-fatality rate as of March 15, 2020 \[[@bb0040]\].

Due to the close similarity to SARS-CoV, the biochemical interactions and the pathogenesis of SARS-CoV-2 are highly likely to be similar \[[@bb0005]\]. The virus entry into the host cell is mainly mediated through the binding of the SARS spike (S) protein to the angiotensin-converting enzyme 2 (ACE-2) receptor on the cell surface \[[@bb0045]\]. Among coronaviruses, the main protease (M^pro^, also called 3CL^pro^) has emerged as the best-described drug target \[[@bb0050]\]. The polyproteins that are translated from the viral RNA are processed by this enzyme together with the papain-like protease(s) \[[@bb0055]\]. The M^pro^ recognizes and acts remarkably on eleven cleavage sites typically Leu-Gln↓(Ser,Ala,Gly) on the large polyprotein 1ab (replicase 1ab) of approximately 790 kDa. Blocking the activity of this enzyme would help in inhibiting viral replication. There are no reported human proteases with a similar cleavage specificity and therefore, inhibitors against this enzyme are less probable to be toxic \[[@bb0040]\]. The three dimensional X-ray crystal structure of this enzyme in complex with α-ketoamide inhibitor 13b (O6K) was recently solved by Zhang et al. \[[@bb0040]\] (PDB ID: [6Y2F](pdb:6Y2F){#ir0005}) which offers an opportunity for structure-based drug design against the enzyme target. Understanding the relevance of the steady rise in the number of infected and death cases in recent time from COVID-19 and lack of effective therapeutic interventions such as drugs and vaccines, computer-aided drug design is an important strategy to be sought after. This rational based drug design will reduce the cost and time incurred in the drug discovery process. Structure-based drug design primarily relies on molecular docking to identify lead molecules against the target proteins from chemical libraries \[[@bb0060],[@bb0065]\]. Compared to the synthetic inhibitors plant based-drugs have less toxicity and much safer to use. The natural products such as traditional medicines and plant-derived compounds (phytochemicals) are the rich sources of promising antiviral drugs \[[@bb0070]\]. Around 44% of the approved antiviral drugs between 1981 and 2006 were derived from natural products \[[@bb0075]\]. The plant extracts have been extensively used and screened for drug molecules to evaluate theirs in vitro antiviral activities. Few examples of medicinal plants with proven antiviral activities include *Phyllanthus amarus* Schum. and Thonn which blocks human immunodeficiency virus (HIV) replication both in vitro and in vivo \[[@bb0080]\]; *Azadirachta indica* Juss. (Neem) shows in vitro and in vivo inhibition properties against Dengue virus type-2 (DENV-2) \[[@bb0085]\]; *Geranium sanguineum* L. significantly inhibits the replication of Herpes simplex virus type-1 and 2 (HSV-1 and HSV-2) in vitro \[[@bb0090]\]; *Acacia nilotica* L. possesses activity against Hepatitis C virus (HCV) in vitro etc. \[[@bb0095]\].

In the present study, we have screened small drug-like molecules from a dataset of phytochemicals possessing antiviral activities using drug-like filters and toxicity studies. The selected molecules were evaluated for their binding affinity to SARS-CoV-2 M^pro^ enzyme using molecular docking. The sequences and structures of SARS-CoV-2 M^pro^ were compared with SARS-CoV M^pro^ and MERS-CoV M^pro^. The identified lead molecules were further examined for their broad-spectrum inhibition potential against SARS-CoV M^pro^ and MERS-CoV M^pro^.

2. Material and methods {#s0010}
=======================

2.1. Ligand preparation {#s0015}
-----------------------

The information about a set of thirty-eight phytochemicals from medicinal plants with antiviral activities was retrieved through literature search \[[@bb0070]\]. The summary of the selected phytochemicals (class, plant source and antiviral activity) is provided in Suppl. Table 1. The two-dimensional structures of the phytochemicals were generated using Chemsketch and modelled into 3D using open Babel and the structure optimization was carried out with an MMFF94 force field \[[@bb0100]\] using our previously defined protocol \[[@bb0105]\]. These optimized structures were used for virtual screening. A set of twelve FDA approved antiviral drugs such as Raltegravir (CID54671008), Dolutegravir (CID54726191), Nelfinavir (CID64143), Lopinavir (CID92727), Zidovudine (CID35370), Nevirapine (CID4463), Simeprevir (24873435), Boceprevir (CID10324367), Zanamivir (CID60855), Oseltamivir (CID65028), Acyclovir (CID135398513) and Ganciclovir (CID135398740) were retrieved from PubChem database \[[@bb0110]\].

2.2. Screening of small drug-like molecules {#s0020}
-------------------------------------------

The phytochemicals were screened based on physicochemical properties obeying Lipinski\'s rule of five (ROF) filters \[[@bb0115]\] and further tested for in silico toxicity studies such as mutagenicity, tumorigenicity, reproductive effects and irritancy. The physicochemical properties of the phytochemicals were determined using DataWarrior program version 4.6.1 \[[@bb0120]\].

2.3. Receptor preparation {#s0025}
-------------------------

The three-dimensional structures of SARS-CoV-2 M^pro^, SARS-CoV M^pro^ and MERS-CoV M^pro^ were retrieved from Protein Data Bank (PDB) (<http://www.rcsb.org/>) using PDB IDs:[6Y2F](pdb:6Y2F){#ir0015}, [3TNT](pdb:3TNT){#ir0020} and [5WKK](pdb:5WKK){#ir0025} at a resolution of 1.95 Å, 1.59 Å and 1.55 Å respectively. The receptors were prepared for molecular docking using our previously defined protocol \[[@bb0125]\]. The binding sites were defined by choosing grid boxes of suitable dimensions around the bound co-crystal ligand. The grid box dimensions for SARS-CoV-2 M^pro^, SARS-CoV M^pro^ and MERS-CoV M^pro^ are represented in [Table 1](#t0005){ref-type="table"} .Table 1The grid box dimensions selected for molecular docking studies.Table 1Target enzymeGrid box dimensionNumber of grid points (npts)Center (xyz coordinates)Grid point spacing (Å)SARS-CoV-2 M^pro^60 × 60 × 6011.476, −1.396. 21.1270.375SARS-CoV M^pro^65 × 65 × 6522.803, 40.132, −10.6200.375MERS-CoV M^pro^65 × 65 × 65−16.001, 25.308, 10.5790.375

2.4. Determination of sequence percentage identity, multiple sequence alignment and pairwise structural clustering {#s0030}
------------------------------------------------------------------------------------------------------------------

The sequence percentage identity of the SARS-CoV-2 M^pro^ to SARS-CoV M^pro^ and MERS-CoV M^pro^ was determined using a standard protein Basic Local Alignment Search (BLASTp) tool (<https://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE=Proteins>). Multiple sequence alignment of the three sequences were performed using CLUSTAL W algorithm \[[@bb0130]\]. Pairwise structural clustering of SARS-CoV-2 M^pro^, SARS-CoV M^pro^ and MERS-CoV M^pro^ was analyzed using UCSF Chimera tool \[[@bb0135]\].

2.5. Validation of docking method {#s0035}
---------------------------------

To check the suitability of molecular docking parameters and algorithm to reproduce the native binding poses, a redocking experiment was performed using the co-crystal compound.

2.6. Molecular docking {#s0040}
----------------------

Molecular docking was executed using AutoDock4.2 software \[[@bb0140]\]. Lamarckian Genetic Algorithm was used for performing molecular docking studies and the docking parameters were chosen from our previously defined protocol \[[@bb0105]\]. A total number of fifty independent docking runs were performed for each compound. The conformational clustering of the poses was performed by considering a root mean square deviation (RMSD) of \<2.0 Å. The most favourable binding poses of the compounds were analyzed by choosing the lowest free energy of binding (ΔG) and the lowest inhibition constant (K~i~) which is calculated using the following equation (Eq. [(1)](#fo0005){ref-type="disp-formula"}):$$K_{i} = \text{exponential}\ \left( {{\mathrm{\Delta}G}/{RT}} \right)$$where ∆G is the binding energy in kcal/mol, R is the universal gas constant (1.987 calK^−1^ mol^−1^) and T is the temperature (298.15 K).

A stable complex is formed between a protein and ligand which exhibits more negative free energy of binding and low K~i~ indicates high potency of an inhibitor \[[@bb0145],[@bb0150]\]. The hydrogen bonds and hydrophobic interactions between the compounds and the target enzymes were studied using LigPlot+ v 1.4.5 \[[@bb0155]\].

3. Results and discussion {#s0045}
=========================

3.1. Selection of phytochemicals for the study {#s0050}
----------------------------------------------

A total of 38 bioactive phytochemicals possessing antiviral activities were selected for the study. These compounds were chosen based on the previous reports of their potent antiviral effects against various pathogenic viruses such as adenovirus, influenza virus, respiratory syncytial virus, human cytomegalovirus, herpes simplex virus, poliovirus, varicella-zoster virus etc. (Suppl. Table 1). The compound set consists of different classes of phytochemicals including active flavonoids (*N* = 14), active organic acids (*N* = 5), active alkaloids (N = 5), active essential oils (*N* = 3), active stilbenes (*N* = 6) and other phytoconstituents (N = 5). The three-dimensional structures the compounds were modelled and optimized. A list of these phytochemicals is enumerated in [Table 2](#t0010){ref-type="table"} . These optimized structures were used further for virtual screening and molecular docking studies.Table 2List of phytochemicals selected for virtual screening.Table 2ClassPhytochemicalsNameFlavonoidsCmpd1(+)-CatechinCmpd2(−)-Epigallocatechin gallate (EGCG)Cmpd3(−)-Epicatechin gallate (ECG)Cmpd4(−)-Epigallocatechin (EGC)Cmpd5RutinCmpd65,7-dimethoxyflavaN-4′-O-β-d-glucopyranosideCmpd75,7,3′-trihydroxy-flavaN-4′-O-β-d-glucopyranosideCmpd8GenisteinCmpd9BaicaleinCmpd10OrientinCmpd11VitexinCmpd12Chrysosplenol CCmpd13Quercetin 3-rhamnoside (Q3R)Cmpd14LuteoforolOrganic acidsCmpd153,4-di-O-caffeoylquinic acidCmpd163,5-di-O-caffeoylquinic acidCmpd17Raoulic acidCmpd18Caffeic acidCmpd19Chlorogenic acidAlkaloidsCmpd20Naphthoindozidine alkaloidCmpd217-demethoxytylophorineCmpd227-demethoxytylophorine N-oxideCmpd23SophoridineCmpd24LycorineEssential oilsCmpd25HimachalolCmpd26α-himachaleneCmpd27β-himachaleneStilbenesCmpd28ResveratrolCmpd29BalanocarpolCmpd30Shegansu BCmpd31Gnetupendin BCmpd32Gnetin DCmpd33IsorhapontigeninOthersCmpd34Caesalmin BCmpd35Bonducellpin DCmpd36Chrysophanic acid (1,8-dihydroxy-3-methylanthraquiN)Cmpd37EmodinCmpd38Hippomanin A

3.2. Screening of small drug-like molecules {#s0055}
-------------------------------------------

From a total of 38 phytochemicals, 10 compounds (four active flavonoids, two active alkaloids, two active essential oils and two other phytoconstituents) were found to be orally bioactive with respect to ROF criterion (Molecular weight (MW) ≤500, cLogP (partition coefficient between n-octanol and water) ≤5, number of hydrogen bond donors (HBD) ≤5 and number of hydrogen bond acceptors (HBA) ≤10 \[[@bb0115]\]) without any significant toxicity issues such as being non-mutagenic, non-tumourigenic, non-irritant and no adverse effects on reproductive health ([Table 3](#t0015){ref-type="table"} ). These drug-like compounds were further taken for molecular docking studies. The drug-attrition rate in preclinical and clinical trials is quite high due to the poor pharmacokinetic studies \[[@bb0125]\] and therefore initial screening of these drug-like molecules can increase the chances of passing through the clinics.Table 3Physicochemical properties of the compounds (asterisk indicates the compounds which passed the toxicity studies). a: Molecular weight, b: Partition coefficient between n-octanol and water, c: Hydrogen bond acceptor, d: Hydrogen bond donor, N: None, H: High, L: Low.Table 3CompoundsMW^a^ (Da)clogP^b^HBA^c^HBD^d^MutagenicTumourigenicReproductive effectiveIrritantCmpd1\*290.2701.508765NNNNCmpd2458.3742.0543118NNNNCmpd3442.3752.4107NNNNCmpd4306.2691.16376NNNNCmpd5610.519−1.25731610NNNNCmpd6\*462.4490.7178104NNNNCmpd7450.395−0.1793117NNNNCmpd8270.2391.627253HHHNCmpd9\*270.2392.335753NNNNCmpd10448.379−0.4237118HNNNCmpd11432.380−0.078107HNNNCmpd12360.3172.123883HNNNCmpd13448.3790.5798117NNNNCmpd14\*290.2701.634865NNNNCmpd15516.4540.7977127NNNNCmpd16516.4540.7977127NNNNCmpd17370.5758.214621NNNNCmpd18180.1590.728543HHHNCmpd19354.310−0.768596NNNNCmpd20353.4603.577740NHNHCmpd21363.4564.086840LHNNCmpd22379.4553.113450LHNNCmpd23\*248.3691.707430NNNNCmpd24\*287.3141.207852NNNNCmpd25\*222.3703.534911NNNNCmpd26204.3564.332100NNNLCmpd27\*204.3564.424700NNNNCmpd28228.2462.829533HNHNCmpd29470.4763.307576NNNNCmpd30514.5284.683985NNNNCmpd31380.3953.88465NNHNCmpd32470.4764.478276NNHNCmpd33258.2722.759543NNHNCmpd34\*388.4582.585661NNNNCmpd35\*404.4571.733572NNNNCmpd36254.2402.685942HNNHCmpd37270.2392.340253HHHHCmpd38634.4540.05271811NNNNControl594.6871.7119124NNNN

3.3. Comparative analysis of SARS-CoV-2 M^pro^, SARS-CoV M^pro^ and MERS-CoV M^pro^ at the sequence and structural level {#s0060}
------------------------------------------------------------------------------------------------------------------------

The primary sequences of SARS-CoV-2 M^pro^ was compared with that of SARS-CoV M^pro^ and MERS-CoV M^pro^ and it was found that SARS-CoV-2 M^pro^ shares identity percentages of 96.08 and 50.65 with that of SARS-CoV M^pro^ and MERS-CoV M^pro^ respectively ([Table 4](#t0020){ref-type="table"} ). The MSA results show the conservation of residues in the three domains-I (residues 1--99), II (residues 100--182) and III (residues 199--306) of the SARS-CoV-2 M^pro^ enzyme which includes catalytic dyad residues His41-Cys145 located in a cleft between domains I and II along with canonical oxyanion hole residues Gly143, Ser144 and Cys145 ([Fig. 1](#f0005){ref-type="fig"} ). Domains I and II have a typical chymotrypsin-like two-β-barrel fold. Domain III possesses a globular structure consisting of five α-helices which is connected to Domain II by a loop of residues 183--198 \[[@bb0160]\]. The pairwise structural imposition of SARS-CoV-2 M^pro^ and SARS-CoV M^pro^ yields an RMSD value of 0.517 Å while an RMSD value of 0.817 Å was obtained when SARS-CoV-2 M^pro^ was superimposed on MERS-CoV M^pro^ ([Fig. 2](#f0010){ref-type="fig"} ). This indicates that SARS-CoV-2 M^pro^ is structurally more close to SARS-CoV M^pro^ as compared to MERS-CoV M^pro^. This comparative study at the sequence and structural level can be exploited for the design of broad-spectrum inhibitors which can block viral infection in host cells.Table 4Standard Protein BLAST result using SARS-CoV-2 M^pro^ as a query sequence.Table 4Subject sequenceMaximum scoreTotal scoreQuery coverageE valuePercent identitySARS-CoV M^pro^623623100%0.096.08%MERS-CoV M^pro^322322100%1e−11450.65%Fig. 1Sequence and structural analysis of SARS-CoV-2 M^pro^. (A) three-dimensional structure of SARS-CoV-2 M^pro^ consists of three domains-I (orange-red), II (yellow) and III (forest green) where domain II and III are connected by a loop (cornflower blue), (B) Multiple Sequence alignment (MSA) of SARS-CoV-2 M^pro^, SARS-CoV M^pro^ and MERS-CoV M^pro^. The red box with white characters indicates strict identity whereas yellow box with red characters corresponds to semi-conserved residues. The secondary structure elements such as α-helices and 310-helices (η) are displayed as squiggles and β-strands and strict β-turns are rendered as arrows and TT letters respectively. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)Fig. 1Fig. 2Structural clustering- (A) SARS-CoV-2 M^pro^ (tan) and SARS-CoV M^pro^ (cyan), (B) SARS-CoV-2 M^pro^ (tan) and MERS-CoV M^pro^ (cyan). (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)Fig. 2

3.4. Binding interaction studies of drug-like molecules with SARS-CoV-2 M^pro^ {#s0065}
------------------------------------------------------------------------------

The molecular docking protocol and algorithm was validated through the redocking experiment. The redocking result of co-crystal compound (6OK) shows an RMSD value of 3.603 Å between the docked and native co-crystal position. This small deviation indicates that the docking protocols and parameters used in the study can reliably estimate the biological conformations of the compounds \[[@bb0165]\].

The ten selected drug-like small molecules were docked into the active site pocket of SARS-CoV-2 M^pro^. The molecular docking results are shown in [Table 5](#t0025){ref-type="table"} . The docking scores were bench-marked using the standard inhibitor, α-ketoamide 13 b (6OK). The α-ketoamide 13 b is a broad-spectrum inhibitor with an IC~50~ value of 0.67 ± 0.18 μM, 0.90 ± 0.29 μM and 0.58 ± 0.22 μM respectively against purified recombinant SARS-CoV-2 M^pro^, SARS-CoV M^pro^ and MERS-CoV M^pro^ \[[@bb0040]\]. On comparing the binding energies and inhibition constants with that of the standard inhibitor, we have shortlisted three lead molecules viz., Bonducellpin D, 5,7-dimethoxyflavanone-4′-O-β-d-glucopyranoside and Caesalmin B. Bonducellpin D and Caesalmin B are terpenoids isolated from the seeds of traditional Chinese medicinal plant *Caesalpinia minax* and exhibit in vitro inhibitory activities against Parainfluenza-3 (PI-3) virus. \[[@bb0170]\] The flavonoid 5,7-dimethoxyflavanone-4′-O-β-d-glucopyranoside has previously been reported to have antiviral activity against PI-3 \[[@bb0175]\]. The molecular interactions of LigPLot results are represented in [Table 6](#t0030){ref-type="table"} . The best-ranked lead molecule i.e., Bonducellpin D interacts with the enzyme target with a binding energy of −9.28 kcal/mol and inhibition constant of 156.75 nM. Bonducellpin D establishes four hydrogen bonds with residues Glu166 and Thr190 and hydrophobic interactions via eight residues (Met49, His164, Met165, Pro168, Asp187, Arg188, Gln189 and Gln192) ([Fig. 3](#f0015){ref-type="fig"}A). The second lead molecule i.e., 5,7-dimethoxyflavanone-4′-O-β-d-glucopyranoside interacts with the target enzyme with a binding energy of −9.23 kcal/mol and inhibition constant of 170.31 nM. This interaction is strengthed by the establishment of five hydrogen bonds with residues Glu166, Thr190 and Gln192 and with the involvement of thirteen residues (Phe140, Leu141, Asn142, Gly143, Ser144, Cys145, His164, Met165, Leu167, Pro168, His172, Arg188 and Gln189) contributing to hydrophobic interactions ([Fig. 3](#f0015){ref-type="fig"}B). The third lead molecule- Caesalmin B interacts with SARS-CoV-2 M^pro^ with a binding energy of −8.82 kcal/mol and inhibition constant of 342.79 nM. The molecular interaction is facilitated through four hydrogen bonds with residues Glu166, Thr190 and Gln192 and hydrophobic interactions via ten residues (His41, Met49, Tyr54, Cys145, His164, Met165, Leu167, Asp187, Arg188 and Glu189) ([Fig. 3](#f0015){ref-type="fig"}C). The standard inhibitor interacts with SARS-CoV-2 M^pro^ with a binding energy of −8.24 kcal/mol and inhibition constant of 905.88 nM. The binding interaction is mediated through four hydrogen bonds with residues Asn142, Cys145 and Glu166, and hydrophobic interactions via fourteen residues (Thr26, His41, Phe140, Leu141, Gly143, Ser144, His163, His164, Met165, Pro168, Asp187, Gln189, Thr190 and Gln192) ([Fig. 3](#f0015){ref-type="fig"}D). Interestingly, the residues His41 and Cys145 which form catalytic dyad residues are also found interacting with the inhibitor. Thus all the three lead molecules have better binding affinity to SARS-CoV-2 M^pro^ compared to the standard inhibitor.Table 5Molecular docking result for selected compounds and control against SARS-CoV-2 M^pro^.Table 5CompoundsNameStructureBinding energy (kcal/mol)Inhibition constant (nM)Cmpd1(+)-Catechin![](t1_lrg.gif)−7.861720Cmpd65,7-dimethoxyflavaN-4′-O-β-d-glucopyranoside![](t2_lrg.gif)−9.23170.31Cmpd9Baicalein![](t3_lrg.gif)−6.5116,950Cmpd14Luteoforol![](t4_lrg.gif)−7.027100Cmpd23Sophoridine![](t5_lrg.gif)−6.7611,120Cmpd24Lycorine![](t6_lrg.gif)−7.672380Cmpd25Himachalol![](t7_lrg.gif)−7.007390Cmpd27β-himachalene![](t8_lrg.gif)−5.8055,970Cmpd34Caesalmin B![](t9_lrg.gif)−8.82342.79Cmpd35Bonducellpin D![](t10_lrg.gif)−9.28156.75Controlα-ketoamide 13b![](t11_lrg.gif)−8.24905.88Table 6LigPlot analysis for top three lead compounds along with the control against SARS-CoV-2 M^pro^.Table 6CompoundsNameHydrogen bondsHydrophobic interactionsCmpd35Bonducellpin DO2.....O(Glu166) (2.83 Å)\
O2.....N(Glu166) (2.91 Å)\
O4.....O(Glu166) (2.61 Å)\
O6.....N(Thr190) (2.92 Å)Met49, His164, Met165, Pro168, Asp187, Arg188, Gln189 and Gln192 (*N* = 8)Cmpd65,7-dimethoxyflavaN-4′-O-β-d-glucopyranosideO8.....O(Glu166) (2.76 Å)\
O1.....N(Glu166) (3.22 Å)\
O7.....N(Thr190) (3.03 Å)\
O7.....N(Thr190) (2.44 Å)\
O9.....O(Gln192) (2.91 Å)Phe140, Leu141, Asn142, Gly143 Ser144, Cys145, His164, Met165, Leu167, Pro168, His172, Arg188 and Gln189 (*N* = 13)Cmpd34Caesalmin BO2.....N(Glu166) (3.32 Å)\
O2.....O(Glu166) (2.46 Å)\
O6.....N(Thr190) (3.01 Å)\
O6.....NE2(Gln192) (2.87 Å)Met49, His41, Tyr54, Cys145, His164, Met165, Leu167, Asp187, Arg188 and Glu189 (N = 10)Controlα-ketoamide 13bN23.....OD1(Asn142) (2.83 Å)\
O37.....SG(Cys145) (3.31 Å)\
O41.....N(Glu166) (3.12 Å)\
O40.....N(Glu166) (2.98 Å)Thr26, His41, Gly143, Phe140, Leu141, Ser144, His163, His164, Met165, Pro168, Asp187, Gln189, Thr190 and Gln192 (N = 14)Fig. 3Binding poses and molecular interactions between lead compounds and SARS-CoV-2 M^pro^. (A) Bonducellpin D, (B) 5,7-dimethoxyflavanone-4′-O-β-d-glucopyranoside, (C) Caesalmin B, (D) α-ketoamide 13b (Control). The binding poses display the target enzyme in ribbon form with structural domains-I (orange-red), II (yellow) and III (forest green) where domain II and III are connected by a loop (cornflower blue) and the bound compounds are rendered as ball-and-stick (purple). The molecular interactions show hydrogen bonds as green dashed lines and hydrophobic interactions as semi-arcs with red eyelashes. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)Fig. 3

3.5. Binding interaction studies of the lead compounds with SARS-CoV M^pro^ and MERS-CoV M^pro^ {#s0070}
-----------------------------------------------------------------------------------------------

Due to the close similarity of SARS-CoV-2 M^pro^ to SARS-CoV M^pro^ and MERS-CoV M^pro^ at the structural level, the identified lead molecules may have broad-spectrum inhibitory activity and therefore, the binding affinities of the lead molecules against the other two target enzymes were studied. The binding energies and inhibition constants of the compounds against SARS-CoV M^pro^ and MERS-CoV M^pro^ are shown in [Table 7](#t0035){ref-type="table"} . The best-ranked lead molecule i.e., Bonducellpin D exhibits binding energies and inhibition constants of −8.64 kcal/mol and 467.11 nM; −8.93 kcal/mol and 284.86 nM against SARS-CoV M^pro^ and MERS-CoV M^pro^ respectively. It binds to SARS-CoV M^pro^ by establishing two hydrogen bonds with Gln189 and hydrophobic interacting residues include His41, Cys44, Met49, Tyr54, Asn142, Cys145, His164, Met165, Glu166, Asp187 and Arg188 (*N* = 11) ([Fig. 4](#f0020){ref-type="fig"}A). Bonducellpin D also shows good molecular interaction with MERS-CoV M^pro^ using four hydrogen bonds with residues His41, Ser147, Cys148 and Glu169 and residues such as Met25, Leu49, Phe143, Leu144, Cys145, Gly146, His166, Gln167, Met168 and Gln192 (*N* = 10) participate in hydrophobic interactions ([Fig. 5](#f0025){ref-type="fig"}A). With binding energies and inhibition constants of −8.94 kcal/mol and 282.15 nM; −8.55 kcal/mol and 539.13 nM against SARS-CoV M^pro^ and MERS-CoV M^pro^ respectively, the second lead molecule i.e., 5,7-dimethoxyflavanone-4′-O-β-d-glucopyranoside also shows broad-spectrum antiviral activities. 5,7-dimethoxyflavanone-4′-O-β-d-glucopyranoside shows favourable interactions with SARS-CoV M^pro^ through seven hydrogen bonds with His163, Glu166, Thr190 and Gln192 and hydrophobic interactions via residues Phe140, Leu141, Gly143, Ser144, Cys145, Met165, Leu167, Pro168, His172, Gln189 and Ala191 (*N* = 11) ([Fig. 4](#f0020){ref-type="fig"}B). It also exhibits good binding to MERS-CoV M^pro^ through four hydrogen bonds via residues Gly146, Gln192 and Gln195 and the interaction is further strengthened through hydrophobic interactions via Met25, His41, Leu49, Cys148, Gln167, Met168, Glu169, Leu170, Ala171, Lys191, Val193 and His194 (*N* = 12) ([Fig. 5](#f0025){ref-type="fig"}B). The third lead compound- Caesalmin B shows binding energies and inhibition constants of −8.71 kcal/mol and 412.24 nM; −9.49 kcal/mol and 111.50 nM against SARS-CoV M^pro^ and MERS-CoV M^pro^ respectively. Caesalmin B shows optimum binding to SARS-CoV M^pro^ by forming two hydrogen bonds with residues Gly143 and Glu166 and hydrophobic interactions via residues His41, Leu141, Asn142, Ser144, Cys145, His163, His164, Met165 and Gln189 (*N* = 9) ([Fig. 4](#f0020){ref-type="fig"}C). It also exhibits good binding to MERS-CoV M^pro^ by establishing three hydrogen bonds with residues Cys145, Cys148 and His166 and hydrophobic interactions via residues Met25, Thr26, Leu27, Phe143, Leu144, Gly146, Ser147, Gln167, Met168, Glu169 and Gln192 (N = 11) ([Fig. 5](#f0025){ref-type="fig"}C). The control shows binding energies and inhibition constants of −8.62 kcal/mol and 482.81 nM; −11.36 kcal/mol and 4.75 nM against SARS-CoV M^pro^ and MERS-CoV M^pro^ respectively. The interaction between the control and SARS-CoV M^pro^ is mediated through two hydrogen bonds with Glu166 and Gln189 and hydrophobic interactions through residues-Thr25, His41, Val42, Cys44, Met49, Tyr54, Leu141, Asn142, Gly143, Ser144, Cys145, His163, His164, Met165, Leu167, Asp187 and Thr190 (*N* = 17) ([Fig. 4](#f0020){ref-type="fig"}D). It also shows good binding to MERS-CoV M^pro^ which involves seven hydrogen bonds with Cys145, Ser147, Cys148, Gln167 and Glu169 and hydrophobic interactions via residues Met25, Thr26, Leu27, His41, Phe143, Leu144, Gly146, His166, Met168, Leu170, Ala171, Gln192, Val193, His194 and Gln195 (*N* = 15) ([Fig. 5](#f0025){ref-type="fig"}D).Table 7Molecular docking results for top 3 leads and control against SARS-CoV M^pro^ and MERS-CoV M^pro^.Table 7SARS-CoV M^pro^MERS-CoV M^pro^CompoundsNameBinding energy (kcal/mol)Inhibition constant (nM)Binding energy (kcal/mol)Inhibition constant (nM)Cmpd35Bonducellpin D−8.66467.11−8.93284.86Cmpd65,7-dimethoxyflavaN-4′-O-β-d-glucopyranoside−8.94282.15−8.55539.13Cmpd34Caesalmin B−8.71412.24−9.49111.50controlα-ketoamide 13b−8.62482.81−11.364.75Fig. 4Binding pose and molecular interaction between lead compounds and SARS-CoV M^pro^. (A) Bonducellpin D, (B) 5,7-dimethoxyflavanone-4′-O-β-d-glucopyranoside, (C) Caesalmin B, (D) α-ketoamide 13b (Control). The binding poses represent the target enzyme as ribbon where helices, sheets and loops are indicated by orange-red, purple and grey respectively and the bound compounds as ball-and-stick (cornflower blue). The molecular interactions are represented by the green dashed lines for hydrogen bonds and semi-arcs with red eyelashes for hydrophobic interactions. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)Fig. 4Fig. 5Molecular interaction between lead compounds and MERS-CoV M^pro^. (A) Bonducellpin D, (B) 5,7-dimethoxyflavanone-4′-O-β-d-glucopyranoside, (C) Caesalmin B, (D) α-ketoamide 13b (Control). The binding poses represent the target enzyme as ribbon where helices, sheets and loops are indicated by orange-red, purple and grey respectively and the bound compounds as ball-and-stick (cornflower blue). The molecular interactions are represented by the green dashed lines for hydrogen bonds and semi-arcs with red eyelashes for hydrophobic interactions. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)Fig. 5

3.6. Comparison of binding affinity of the lead molecules with FDA-approved antiviral drugs {#s0075}
-------------------------------------------------------------------------------------------

The binding energies and inhibition constants of the phytochemicals with the SARS-CoV-2 M^pro^ enzyme were compared with that of a set of twelve FDA approved antiviral drugs-a) Viral integrase inhibitors (Raltegravir and Dolutegravir) b) HIV-1 protease inhibitors (Nelfinavir and Lopinavir) c) HIV-1 reverse transcriptase inhibitors (Zidovudine and Nevirapine) d) HCV NS3/NS4B protease inhibitors (Simeprevir and Boceprevir) e) Neuraminidase inhibitors (Zanamivir and Oseltamivir) and f) HSV-1 thymidine kinase inhibitors (Acyclovir and Ganciclovir) (Suppl. Table 2). The results show that the binding energies and inhibition constant values of the phytochemicals were lower as compared to the majority of the approved antiviral drugs except for Nelfinavir (−9.54 kcal/mol), Boceprevir (−9.3 kcal/mol) and Simeprevir (−11.1 kcal/mol) which indicates that these phytochemicals have higher binding affinity to the target enzyme as compared to the antiviral drugs.

4. Conclusion {#s0080}
=============

With the exponential increase in the mortality rate and lack of therapeutic interventions for the treatment of SARS-CoV-2 infection in humans, the discovery of novel drug molecules is crucial. SARS-CoV-2 M^pro^ is a well-characterized drug target and its recent structural elucidation through X-ray crystallography has opened an avenue for structure-based drug design. Herein, we have explored a small library of phytochemicals with previously reported antiviral properties for the identification of small molecular inhibitors against SARS-CoV-2 M^pro^ using a computational approach. We identified three lead molecules- Bonducellpin D, 5,7-dimethoxyflavanone-4′-O-β-d-glucopyranoside and Caesalmin B which exhibit higher binding affinities as compared to the control. These lead molecules also demonstrate broad-spectrum antiviral activities against SARS-CoV M^pro^ and MERS-CoV M^pro^. The current findings need further validations through in vitro and in vivo studies for developing into drug candidate molecules.
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